Stock listing
Lang & Schwarz:A2PCBM Alector, Inc. Aktie
German listing (Lang & Schwarz) of Alector, Inc. · home listing NASDAQ:ALEC
Follow Alector, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ALEC
$2.34 USD -0.23 (-9.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ALEC
- Day range
- $2.27 – $2.48 USDNov 20, 2026
- Volume
- 1.95M sharesNov 20, 2026
- Market cap
- $347.6M USDAt the close on Nov 20, 2026 · price × 148.9M shares outstanding
- 52-week range
- $1.09 – $2.84 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.77M USDMedian day 1.46M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALEC · Home | $2.335 USD | -0.235 (-9.1%) | 1,953,176 | $2.28 | $2.48 | $2.27 | $2.57 | Close on Nov 20, 2026 |
| Frankfurt:0Z2 | €2.054 EUR | -0.248 (-10.8%) | — | €2.054 | €2.054 | €2.054 | €2.302 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALEC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.335 | -0.235 | -9.1% | $2.28 | $2.48 | $2.27 | 1,953,176 | |
| $2.57 | +0.01 | +0.4% | $2.57 | $2.74 | $2.51 | 2,133,508 | |
| $2.56 | -0.01 | -0.4% | $2.57 | $2.61 | $2.50 | 1,268,972 | |
| $2.57 | +0.03 | +1.2% | $2.54 | $2.655 | $2.515 | 2,769,779 | |
| $2.54 | +0.09 | +3.7% | $2.59 | $2.59 | $2.30 | 1,799,131 | |
| $2.45 | -0.18 | -6.8% | $2.66 | $2.66 | $2.39 | 1,871,735 | |
| $2.63 | +0.10 | +4.0% | $2.55 | $2.84 | $2.54 | 3,476,459 | |
| $2.53 | +0.07 | +2.8% | $2.40 | $2.64 | $2.385 | 3,258,445 | |
| $2.46 | +0.17 | +7.4% | $2.29 | $2.555 | $2.28 | 2,336,637 | |
| $2.29 | +0.20 | +9.6% | $2.18 | $2.31 | $2.085 | 1,020,180 | |
| $2.09 | -0.19 | -8.3% | $2.27 | $2.28 | $2.02 | 1,272,552 | |
| $2.28 | +0.23 | +11.2% | $2.14 | $2.295 | $2.08 | 1,477,964 | |
| $2.05 | -0.10 | -4.7% | $2.17 | $2.245 | $2.03 | 1,429,027 | |
| $2.15 | -0.06 | -2.7% | $2.20 | $2.23 | $2.09 | 952,460 | |
| $2.21 | -0.03 | -1.3% | $2.20 | $2.25 | $2.09 | 1,110,898 | |
| $2.24 | -0.01 | -0.4% | $2.25 | $2.32 | $2.20 | 1,460,699 | |
| $2.25 | +0.15 | +7.1% | $2.08 | $2.26 | $2.05 | 1,910,158 | |
| $2.10 | +0.27 | +14.8% | $1.82 | $2.12 | $1.82 | 4,569,623 | |
| $1.83 | 0.00 | 0.0% | $1.85 | $1.94 | $1.79 | 2,659,359 | |
| $1.83 | 0.00 | 0.0% | $1.81 | $1.84 | $1.72 | 1,410,707 | |
| $1.83 | -0.04 | -2.1% | $1.86 | $1.88 | $1.74 | 1,479,754 | |
| $1.87 | -0.10 | -5.1% | $1.97 | $2.00 | $1.85 | 1,114,345 | |
| $1.97 | +0.02 | +1.0% | $1.96 | $2.04 | $1.915 | 2,021,249 | |
| $1.95 | +0.11 | +6.0% | $1.85 | $1.99 | $1.765 | 2,367,825 | |
| $1.84 | -0.07 | -3.7% | $2.18 | $2.18 | $1.79 | 5,157,884 | |
| $1.91 | +0.03 | +1.6% | $1.92 | $1.95 | $1.85 | 1,630,377 | |
| $1.88 | +0.01 | +0.5% | $1.84 | $1.919 | $1.82 | 2,912,375 | |
| $1.87 | -0.21 | -10.1% | $2.07 | $2.08 | $1.775 | 2,843,592 | |
| $2.08 | 0.00 | 0.0% | $2.08 | $2.14 | $2.02 | 1,630,342 | |
| $2.08 | +0.06 | +3.0% | $2.01 | $2.145 | $2.00 | 3,118,490 | |
| $2.02 | +0.10 | +5.2% | $1.90 | $2.06 | $1.88 | 6,453,307 | |
| $1.92 | +0.11 | +6.1% | $1.78 | $1.92 | $1.73 | 3,972,727 | |
| $1.81 | -0.18 | -9.0% | $2.08 | $2.23 | $1.75 | 10,177,270 | |
| $1.99 | +0.18 | +9.9% | $2.725 | $2.73 | $1.96 | 89,983,688 | |
| $1.81 | -0.05 | -2.7% | $1.89 | $1.965 | $1.80 | 1,170,910 | |
| $1.86 | +0.01 | +0.5% | $1.82 | $1.91 | $1.805 | 774,594 | |
| $1.85 | -0.02 | -1.1% | $1.88 | $1.949 | $1.83 | 792,697 | |
| $1.87 | -0.05 | -2.6% | $1.95 | $1.95 | $1.86 | 960,739 | |
| $1.92 | -0.03 | -1.5% | $1.92 | $1.955 | $1.86 | 713,343 | |
| $1.95 | +0.03 | +1.6% | $1.92 | $2.05 | $1.90 | 1,024,565 | |
| $1.92 | -0.10 | -5.0% | $2.02 | $2.05 | $1.905 | 849,547 | |
| $2.02 | +0.01 | +0.5% | $2.00 | $2.02 | $1.95 | 1,182,749 | |
| $2.01 | +0.08 | +4.1% | $1.97 | $2.035 | $1.93 | 1,464,201 | |
| $1.93 | +0.02 | +1.0% | $1.90 | $1.945 | $1.85 | 1,281,187 | |
| $1.91 | +0.06 | +3.2% | $1.85 | $1.91 | $1.79 | 2,119,032 | |
| $1.85 | -0.075 | -3.9% | $1.96 | $1.97 | $1.83 | 931,237 | |
| $1.925 | -0.11 | -5.4% | $2.06 | $2.06 | $1.91 | 622,263 | |
| $2.035 | -0.175 | -7.9% | $2.19 | $2.209 | $1.985 | 715,905 | |
| $2.21 | +0.07 | +3.3% | $2.15 | $2.225 | $2.095 | 2,467,755 | |
| $2.14 | 0.00 | 0.0% | $2.17 | $2.22 | $2.02 | 4,699,046 | |
| $2.14 | -0.13 | -5.7% | $2.22 | $2.24 | $2.00 | 3,781,817 | |
| $2.27 | -0.20 | -8.1% | $2.47 | $2.47 | $2.25 | 505,801 | |
| $2.47 | +0.01 | +0.4% | $2.38 | $2.61 | $2.33 | 916,854 | |
| $2.46 | -0.05 | -2.0% | $2.52 | $2.575 | $2.44 | 496,601 | |
| $2.51 | -0.21 | -7.7% | $2.70 | $2.75 | $2.435 | 2,792,296 | |
| $2.72 | +0.32 | +13.3% | $2.40 | $2.76 | $2.40 | 1,672,778 | |
| $2.40 | +0.14 | +6.2% | $2.24 | $2.486 | $2.22 | 482,393 | |
| $2.26 | -0.08 | -3.4% | $2.32 | $2.35 | $2.23 | 610,059 | |
| $2.34 | -0.05 | -2.1% | $2.39 | $2.44 | $2.315 | 542,221 | |
| $2.39 | -0.07 | -2.8% | $2.44 | $2.50 | $2.39 | 706,964 | |
| $2.46 | +0.10 | +4.2% | $2.38 | $2.515 | $2.26 | 996,494 | |
| $2.36 | +0.06 | +2.6% | $2.32 | $2.455 | $2.28 | 558,276 | |
| $2.30 | -0.06 | -2.5% | $2.36 | $2.465 | $2.29 | 738,144 | |
| $2.36 | +0.10 | +4.4% | $2.28 | $2.37 | $2.20 | 728,094 | |
| $2.26 | -0.17 | -7.0% | $2.40 | $2.46 | $2.185 | 662,589 |
- Ticker
- Lang & Schwarz:A2PCBM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
Alector Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Oct 13, 2026
Corporate Update (October 2026)
Corporate update · 47 slides
Latest news
Alector Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed $2.29 (+9.6%) on Nov 6, 2026
Alector Announces Pricing of Underwritten Offering
Oct 16, 2026
Closed $1.84 (-3.7%) on Oct 16, 2026
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Oct 7, 2026
Closed $2.02 (+5.2%) on Oct 8, 2026
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
Oct 5, 2026
Closed $1.99 (+9.9%) on Oct 5, 2026
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed $1.78 (-2.7%) on Aug 7, 2026
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Closed $2.10 (-13.9%) on May 8, 2026
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
Apr 29, 2026
Closed $2.37 (+3.0%) on Apr 30, 2026
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Feb 25, 2026
Closed $2.56 (+7.1%) on Feb 26, 2026
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
Feb 24, 2026
Closed $2.19 (+4.3%) on Feb 24, 2026
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Dec 12, 2025
Closed $1.49 (+2.1%) on Dec 12, 2025
Alector, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 129 in all · newest Nov 5, 2026 · oldest 2019
- Calls
- 5 calls with a replay · 5 with a transcript · latest Aug 7, 2025
- Decks
- 4 decks · latest Oct 13, 2026
Where Alector, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALEC · Home listing | NASDAQ | United States | USD |
| Tradegate:0Z2 | Tradegate | Germany | EUR |
| LS Exchange:A2PCBM | LS Exchange | Germany | EUR |
| gettex:0Z2 | gettex | Germany | EUR |
| Lang & Schwarz:A2PCBM · This page | Lang & Schwarz | Germany | EUR |
| BOATS:ALEC | BOATS | United States | USD |
| Dusseldorf:0Z2 | Dusseldorf | Germany | EUR |
| Frankfurt:0Z2 | Frankfurt | Germany | EUR |
| Hamburg:0Z2 | Hamburg | Germany | EUR |
| Munich:0Z2 | Munich | Germany | EUR |
| Stuttgart:0Z2 | Stuttgart | Germany | EUR |
Valuation
P/E 8.4× against a median of 17.2×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $208.9M USD
- P/E
- 8.4×
- EV/sales
- 1.2×
- EV/EBITDA
- 4.9×
- Price/book
- 3.0×
- Gross margin
- Not reported
- Operating margin
- 20.2%
- Net margin
- 23.9%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.72
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alector, Inc. · NASDAQ:ALEC | US$347.6M | US$208.9M | 8.4× | 1.2× | 4.9× | 3.0× | 23.9% | 0.0× | 1.72 |
| Puma Biotechnology Inc · NASDAQ:PBYI | US$364.5M | US$255.9M | 15.3× | 1.1× | 5.8× | 2.5× | 10.3% | 0.0× | 0.88 |
| PureTech Health PLC · LSE:PRTC | US$364.3M | US$160.3M | n/a | 34.4× | n/a | 0.9× | n/a | 0.1× | n/a |
| Lumosa Therapeutics Co Ltd · TPEX:6535 | US$362.3M | US$343.1M | n/a | 329× | n/a | 9.7× | n/a | 0.0× | n/a |
| Aspen Neuroscience, Inc. · NASDAQ:ASPE | US$361.2M | US$288.8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| AbClon, Inc. · KRX:174900 | US$348.2M | US$321.1M | n/a | 80.9× | n/a | 8.8× | −328.3% | 0.0× | n/a |
| Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617 | US$347.3M | US$296.6M | n/a | 232× | n/a | 4.9× | −389.6% | 0.0× | n/a |
| Onconic Therapeutics, Inc. · KRX:476060 | US$346.5M | US$299.7M | 19.1× | 4.9× | n/a | 5.4× | 29.5% | 0.0× | n/a |
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| Median of the others | US$347.8M | US$298.2M | 17.2× | 232× | 4.6× | 5.2× | −159.0% | 0.0× | 0.88 |
Forecasts
3 strong buy · 2 hold · 1 sell · 1 strong sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.42 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.93 · 6 analysts
- Revenue, year to Dec 2026
- 221M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Arnon Rosenthal | Chief Executive Officer, Co-Founder |
| Neil Berkley | Chief Financial Officer and Chief Business Officer |
| Danielle Pasqualone | General Counsel |
| Hua Long | Senior Vice President and Head of Research |
| Caiyan Li | Head of Clinical Development & Data Science |
| Clare Hunt | Chief People and Places Officer |
Board
| Director | Role |
|---|---|
| Elizabeth Garofalo | Board Member |
| Errol De Souza | Board Member |
| Kristine Yaffe | Board Member |
| Mark Altmeyer | Board Member |
| Paula Hammond | Board Member |
| Richard H. Scheller | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Alector (NASDAQ:ALEC) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Alector (NASDAQ:ALEC) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 4:30 PM ET | Replay |
| Alector (NASDAQ:ALEC) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 4:30 PM ET | Replay |
| Alector (NASDAQ:ALEC) Q4 2023 Earnings Call | Tue, Feb 27, 2024 · 4:30 PM ET | Replay |
| Alector (NASDAQ:ALEC) Q2 2023 Earnings Call | Thu, Aug 03, 2023 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +9.6% |
| Q2 2026 | Aug 6, 2026 · After close | −2.7% |
| Q1 2026 | May 7, 2026 · After close | −13.9% |
| Q4 2025 | Mar 3, 2026 | −2.7% |
| Q3 2025 | Nov 6, 2025 · After close | −1.5% |
| Q2 2025 | Aug 7, 2025 · After close | +47.3% |
| Q1 2025 | May 8, 2025 · After close | +12.5% |
| Q4 2024 | Feb 25, 2025 · Before open | −0.6% |
| Q3 2024 | Nov 6, 2024 · After close | +7.6% |
| Q2 2024 | Aug 7, 2024 · After close | +3.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +0.2% |
| Q4 2023 | Feb 27, 2024 · After close | −0.3% |
| Q3 2023 | Nov 7, 2023 · After close | −7.3% |
| Q2 2023 | Aug 3, 2023 · After close | +32.4% |
| Q1 2023 | May 4, 2023 · After close | +10.3% |
| Q4 2022 | Feb 28, 2023 · After close | +3.0% |
| Q3 2022 | Nov 8, 2022 · After close | −19.8% |
| Q2 2022 | Aug 4, 2022 · After close | +15.3% |
| Q1 2022 | May 5, 2022 · After close | −6.5% |
| Q4 2021 | Feb 24, 2022 · After close | −0.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (October 2026) | Corporate update | 47 slides | Oct 13, 2026 |
| Investor Presentation (October 2026) | Investor deck | 37 slides | October 2026 |
| The 7th CNS Drug Delivery Summit (December 2025) | Conference | 24 slides | Dec 11, 2025 |
| Technical Presentation (September 2025) | Technical | 55 slides | September 2025 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$75.03M · US$2.05 a share · Morgan Stanley & Co. LLC +1 Dealers: Morgan Stanley & Co. LLC (co-lead), BTIG, LLC (co-lead) Buyers: TCGX; BVF Partners; ADAR1 Capital Management; Deep Track Capital Use of proceeds: General corporate purposes, including research, development and manufacturing of product candidates, working capital, capex and possible acquisitions | Oct 16, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$19.00 a share on Feb 6, 2019.
- Price
- US$19.00 a share
- Shares offered
- 9,250,000 shares of common stock
- Offering size
- US$175.8 million
- Underwriters' option
- Up to 1,387,500 more shares
- Underwriters
- Morgan Stanley, BofA Merrill Lynch, Cowen, Barclays · In the order on the cover
- Shares delivered
- On or about Feb 11, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 12, 2018 |
| Filed publicly | Jan 7, 2019 |
| Amended twice | Newest Feb 6, 2019 |
| Shares registered with an exchange | Jan 31, 2019 |
| Declared effective by the SEC | Feb 6, 2019 |
| Final prospectus, with the price | Feb 7, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 7, 2019 |
| EFFECT · Notice that a registration is effective | Feb 6, 2019 |
| FWP · Free writing prospectus | Feb 6, 2019 |
| S-1/A · Registration statement, amended | Feb 6, 2019 |
| CORRESP · Letter to the SEC | Feb 4, 2019 |
| CORRESP · Letter to the SEC | Feb 4, 2019 |
| CERT · Exchange's certificate of listing | Feb 4, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 31, 2019 |
| S-1/A · Registration statement, amended | Jan 29, 2019 |
| CORRESP · Letter to the SEC | Jan 7, 2019 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 7, 2019 |
| S-1 · Registration statement | Jan 7, 2019 |
| UPLOAD · Letter from the SEC | Dec 20, 2018 |
| DRSLTR · Letter to the SEC with a draft | Dec 17, 2018 |
| UPLOAD · Letter from the SEC | Dec 4, 2018 |
| DRSLTR · Letter to the SEC with a draft | Nov 16, 2018 |
| DRS/A · Draft registration statement, amended | Nov 16, 2018 |
| UPLOAD · Letter from the SEC | Nov 7, 2018 |
| DRSLTR · Letter to the SEC with a draft | Oct 12, 2018 |
| DRS · Draft registration statement | Oct 12, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 7, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.0M | 100.6M | 97.1M | 133.6M | 207.1M | 21.1M | 21.2M | 27.7M | 3.73M | 416.0K |
| Cost of revenue | 9.66M | 185.9M | 8.85M | 8.47M | 189.4M | 156.9M | 100.5M | 73.0M | 29.9M | 13.7M |
| Gross profit | 11.4M | -85.4M | 88.2M | 133.6M | 207.1M | 21.1M | 21.2M | 27.7M | -26.2M | -13.3M |
| Research and development | 123.1M | 185.9M | 192.1M | 210.4M | 189.4M | 156.9M | 100.5M | 73.0M | 29.9M | 13.7M |
| Selling, general and administrative | 54.0M | 57.4M | 56.7M | 61.0M | 55.0M | 59.4M | 35.1M | 11.9M | 6.50M | 1.87M |
| Operating income | -156.0M | -145.0M | -151.7M | -137.8M | -37.4M | -195.2M | -114.4M | -57.3M | -32.7M | -15.1M |
| Depreciation and amortization | 5.72M | 5.41M | 5.72M | 5.71M | 6.33M | 5.87M | 3.77M | 1.02M | 680.0K | 201.0K |
| EBITDA | -150.3M | -139.6M | -146.0M | -132.1M | -31.0M | -189.3M | -110.6M | -56.3M | -32.0M | -14.9M |
| Interest expense | 16.3M | 8.31M | 0 | 0 | 0 | 0 | 0 | |||
| Income before tax | -142.8M | -118.9M | -125.1M | -130.1M | -36.3M | -190.2M | -105.4M | -52.2M | -32.5M | -15.1M |
| Income tax | 168.0K | 128.0K | 5.21M | 3.25M | 0 | 0 | 0 | 5.04M | 0 | 0 |
| Net income | -142.9M | -119.0M | -130.4M | -133.3M | -36.3M | -190.2M | -105.4M | -52.2M | -32.5M | -15.1M |
| Earnings per share, basic | -1.39 | -1.23 | -1.56 | -1.62 | -0.45 | -2.45 | -1.71 | -4.62 | -3.55 | -1.78 |
| Earnings per share, diluted | -1.39 | -1.23 | -1.56 | -1.62 | -0.45 | -2.45 | -1.71 | -4.62 | -3.55 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 65.8M | 33.0M | 74.6M | 154.3M | 329.2M | 50.0M | 89.6M | 65.5M | 32.5M | 50.8M |
| Short-term investments | 190.2M | 380.4M | 474.3M | 558.5M | 406.1M | 363.3M | 263.4M | 224.9M | ||
| Receivables | 2.59M | 7.39M | 0 | 200.2M | 218.0K | |||||
| Inventory | 1 | |||||||||
| Current assets | 266.5M | 424.8M | 565.8M | 726.4M | 749.7M | 421.5M | 357.4M | 293.2M | 233.0M | 51.2M |
| Property, plant and equipment | 10.8M | 17.1M | 21.9M | 25.5M | 27.3M | 30.2M | 33.9M | 10.9M | 2.83M | 2.54M |
| Total assets | 293.2M | 468.3M | 621.8M | 787.6M | 814.7M | 488.3M | 421.9M | 308.4M | 236.1M | 54.1M |
| Accounts payable | 1.69M | 2.21M | 3.77M | 4.19M | 4.75M | 3.00M | 278.0K | 126.0K | 1.14M | 1.15M |
| Current liabilities | 69.5M | 125.1M | 177.9M | 93.8M | 139.6M | 68.1M | 62.0M | 47.9M | 27.4M | 1.51M |
| Long-term debt | 9.32M | 9.39M | 0 | |||||||
| Total debt | 10.4M | 10.0M | 0 | 43.3M | 47.6M | 51.3M | 48.0M | |||
| Total liabilities | 262.6M | 341.5M | 487.7M | 573.2M | 513.9M | 220.7M | 227.2M | 195.2M | 288.1M | 79.0M |
| Shareholders' equity | 30.6M | 126.8M | 134.2M | 214.4M | 300.7M | 267.5M | 194.7M | -97.4M | -52.0M | -24.9M |
| Shares outstanding | 110.4M | 99.1M | 84.9M | 82.9M | 82.0M | 79.3M | 69.1M | 13.8M | 79.6M | 8.50M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -184.0M | -229.9M | -184.2M | -20.3M | 298.6M | -166.7M | -99.3M | 127.5M | -17.8M | -13.0M |
| Capital spending | -41.0K | -1.25M | -2.38M | -4.12M | -3.25M | -5.03M | -15.3M | -1.88M | -801.0K | -2.25M |
| Free cash flow | -184.1M | -231.2M | -186.5M | -24.4M | 295.3M | -171.8M | -114.6M | 125.6M | -18.6M | -15.2M |
| Cash from investing | 196.6M | 107.1M | 101.9M | -159.0M | -49.7M | -105.1M | -48.9M | -224.1M | -801.0K | -2.25M |
| Cash from financing | 20.2M | 81.5M | 2.55M | 4.51M | 30.3M | 232.1M | 172.4M | 131.1M | -15.0K | -77.0K |
| Share buybacks | 30.3M | 7.51M | -92.0K | -1.90M | -15.0K | -77.0K | ||||
| Change in cash | 32.8M | -41.2M | -79.7M | -174.8M | 279.2M | -39.7M | 24.2M | 34.5M | -18.6M | -15.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 23, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Oct 16, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 16, 2026 | Material contract | SEC |
| FWP · Free writing prospectus | Oct 16, 2026 | Offer document | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 14, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 18, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 7, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 28, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Mar 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Mar 12, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 26, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 12, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 21, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 30, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 28, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| SC 13G · Big-stake notice | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 25, 2024 | Current report | SEC |
| 8-K · Current report | Nov 14, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 22, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
This page holds 200 of 631 filings. Open Filings
Cap table
Built by 6ix from Alector, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 148,877,074
- Fully diluted
- 148,877,074
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 148,877,074 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 148,877,074 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Louis J Lavigne Jr Other companies: DocuSign, Inc. (Director · Apr 26, 2018 – Jun 17, 2019 · Past); NovoCure Limited (Director · Oct 1, 2015 – May 31, 2017 · Past); Zynga Inc (Director · Apr 23, 2015 – May 23, 2022 · Past); Depomed Inc (Director · Jul 6, 2013 – May 8, 2018 · Past); Accuray Incorporated (Director · Sep 4, 2009 – Nov 30, 2020 · Past); BMC Software Inc (Director · Aug 22, 2006 – Sep 10, 2013 · Past); Kyphon Inc (Director · Jul 31, 2006 – Nov 2, 2007 · Past); Arena Pharmaceuticals Inc (Director · Jul 28, 2006 – Jul 28, 2006 · Past); Equinix, Inc. (Director · Jun 8, 2006 – Jun 8, 2006 · Past) | Director · Since at least Feb 6, 2019 |
| Terrance McGuire Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past) | Director · Feb 6, 2019 – Sep 11, 2023 · Past |
| Linda Rubinstein Other companies: Nektar Therapeutics (Chief Financial Officer · Since at least May 15, 2026); Adverum Biotechnologies Inc (CHIEF FINANCIAL OFFICER · Since at least Dec 12, 2022); Five Prime Therapeutics Inc (Interim CFO · Apr 13, 2018 – Apr 13, 2018 · Past); Solexa Inc (VP and CFO · Feb 2, 2006 – Jan 26, 2007 · Past) | Interim Chief Financial Ofcr · Sep 8, 2021 – Sep 8, 2021 · Past |
| Elizabeth Garofalo Other companies: Xenon Pharmaceuticals Inc. (Director · Since at least Jun 3, 2021); ACADIA Pharmaceuticals Inc. (Director · Since at least Sep 29, 2020); Exicure, Inc. (Director · Mar 5, 2021 – Jun 13, 2022 · Past) | Board Member · Since at least Sep 23, 2021 |
| Shehnaaz Suliman Other companies: 10x Genomics, Inc. (Member · Since at least Sep 11, 2019); Ultragenyx Pharmaceutical Inc. (Director · Since at least Jan 30, 2019); Theravance Biopharma, Inc. (SVP, Corp Dev & Strategy · Aug 1, 2017 – Feb 20, 2019 · Past) | President and COO · Dec 9, 2019 – Dec 10, 2021 · Past |
| Dave Wehner Other companies: Aurora Innovation, Inc. (Director · Since at least Feb 27, 2026); Meta Platforms, Inc. (Chief Financial Officer · Apr 24, 2019 – Aug 15, 2022 · Past) | Director · May 10, 2019 – Jun 12, 2024 · Past |
| Errol B Desouza Other companies: Royalty Pharma plc (Director · Jun 7, 2024 – May 13, 2025 · Past); Cyclerion Therapeutics, Inc. (Director · Nov 30, 2023 – Nov 30, 2023 · Past) | Director · Since at least Mar 19, 2024 |
| Marc Grasso Other companies: Kyverna Therapeutics, Inc. (Chief Financial Officer · Since at least Jun 30, 2025); Kura Oncology, Inc. (CFO, CBO · Aug 21, 2018 – Jan 26, 2022 · Past) | Chief Financial Officer · Since at least Feb 7, 2022 |
| Mark Altmeyer Other companies: Myovant Sciences Ltd (Director · Oct 26, 2016 – Aug 31, 2018 · Past); Sio Gene Therapies Inc (Pres (ASG) & Chief Comm. Ofc. · Jun 10, 2015 – Mar 15, 2018 · Past) | Board Member · Since at least Mar 19, 2024 |
| Tillman U Gerngross Other companies: Invivyd, Inc. (Chief Executive Officer, Director · Aug 5, 2021 – Jan 30, 2022 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past) | Director · Feb 6, 2019 – Jun 14, 2023 · Past |
All 26 people
| Person | Seat |
|---|---|
| Sara Kenkare-Mitra Other companies: Unicycive Therapeutics, Inc. (Director · Since at least Jul 28, 2025) | President and Head of R&D · Since at least Jun 2, 2025 |
| Arnon Rosenthal | Chief Executive Officer, Director · Since at least Jun 2, 2026 |
| Caiyan Li | Head of Clinical Development & Data Science · Since at least Nov 4, 2026 |
| Calvin Yu | Vice President, Finance · Feb 6, 2019 – Jul 2, 2021 · Past |
| Clare Hunt | Chief People and Places Officer · Since at least Nov 4, 2026 |
| Danielle Pasqualone | General Counsel · Since at least Nov 4, 2026 |
| Errol De Souza | Board Member · Since at least Nov 5, 2026 |
| Gary Romano | Chief Medical Officer · Oct 1, 2023 – Mar 3, 2025 · Past |
| Grace Wong-Sarad | Principal Accounting Officer · Since at least Jun 20, 2025 |
| Hua Long | Senior Vice President and Head of Research · Since at least Nov 4, 2026 |
| Kristine Yaffe | Director · Since at least Jun 17, 2021 |
| Neil Berkley | Chief Financial Officer and Chief Business Officer · Since at least Jun 20, 2025 |
| Paula Hammond | Board Member · Since at least Mar 20, 2020 |
| Richard H. Scheller | Board Member · Since at least Jun 17, 2026 |
| Robert King | Chief Development Officer · Feb 6, 2019 – Oct 1, 2022 · Past |
| Robert Paul | Chief Medical Officer · Feb 6, 2019 – Aug 9, 2021 · Past |
Log in to ask 6ix AI your own questions about Alector, Inc.